BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24013231)

  • 1. Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.
    Cowling VH; Turner SA; Cole MD
    Oncogene; 2014 Jul; 33(27):3519-27. PubMed ID: 24013231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
    Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
    Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
    Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
    Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
    Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
    Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.
    Scholtysik R; Kreuz M; Klapper W; Burkhardt B; Feller AC; Hummel M; Loeffler M; Rosolowski M; Schwaenen C; Spang R; Stein H; Thorns C; Trümper L; Vater I; Wessendorf S; Zenz T; Siebert R; Küppers R;
    Haematologica; 2010 Dec; 95(12):2047-55. PubMed ID: 20823134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
    Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
    Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
    Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
    EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
    Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
    Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
    Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMG-I/Y, a new c-Myc target gene and potential oncogene.
    Wood LJ; Mukherjee M; Dolde CE; Xu Y; Maher JF; Bunton TE; Williams JB; Resar LM
    Mol Cell Biol; 2000 Aug; 20(15):5490-502. PubMed ID: 10891489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.
    Cinti C; Leoncini L; Nyongo A; Ferrari F; Lazzi S; Bellan C; Vatti R; Zamparelli A; Cevenini G; Tosi GM; Claudio PP; Maraldi NM; Tosi P; Giordano A
    Am J Pathol; 2000 Mar; 156(3):751-60. PubMed ID: 10702389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
    Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
    Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
    Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
    Bemark M; Neuberger MS
    Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
    Gregory MA; Hann SR
    Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.